Prevention of HER‐2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12

No abstract is available for this paper.

• Publication year

  2003

• Venue

  International Journal of Cancer

• Publication date

  2003-06-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.11092PMID 12704673
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.

  2002cited by this paper
• Estrogen Receptor-dependent and Estrogen Receptor-independent Pathways for Tamoxifen and 4-Hydroxytamoxifen-induced Programmed Cell Death*

  2002cited by this paper
• Anti-oestrogenic prevention of breast cancer — the make or break point

  2002cited by this paper
• Combined effects on tumor growth and metastasis by anti-estrogenic and antiangiogenic therapies in MMTV-neu mice

  2002cited by this paper
• Estrogen receptor beta in breast cancer.

  2002cited by this paper
• Molecular targets for breast cancer therapy and prevention

  2001cited by this paper
• Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice

  2001cited by this paper
• Beyond Tamoxifen

  2001cited by this paper
• Age and stage dependency of estrogen receptor expression by lymphocyte precursors

  2001cited by this paper
• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination

  2001cited by this paper
• DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2

  2000cited by this paper
• Immunoprevention of cancer: is the time ripe?

  2000cited by this paper
• p185neu protein is required for tumor and anchorage‐independent growth, not for cell proliferation of transgenic mammary carcinoma

  2000cited by this paper
• Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.

  2000cited by this paper
• Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta - regulation by selective estrogen receptor modulators and importance in breast cancer

  2000cited by this paper
• HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

  2000cited by this paper
• Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model.

  2000cited by this paper
• The oestrogen receptor and its selective modulators in gynaecological and breast cancer.

  2000cited by this paper
• Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

  2000cited by this paper
• Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.

  2000cited by this paper
• Tamoxifen prevention of breast cancer: an instance of the fingerpost.

  1999cited by this paper
• Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer

  1999cited by this paper
• Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin.

  1999cited by this paper
• Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

  1998cited by this paper
• Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.

  1998cited by this paper
• Genetic immunization against neu /erbB2 transgenic breast cancer

  1998cited by this paper
• Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice

  1998cited by this paper
• Tamoxifen enhances interferon-regulated gene expression in breast cancer cells

  1997cited by this paper
• Effect of interleukin 12 on tumor induction by 3-methylcholanthrene.

  1996cited by this paper
• Prevention of breast tumour development in vivo by downregulation of the p185neureceptor

  1995cited by this paper
• Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

  1995cited by this paper
• Inhibition of angiogenesis in vivo by interleukin 12.

  1995cited by this paper
• Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

  1992cited by this paper
• Mammary noduligenesis and tumorigenesis in pathogen-free C3Hf mice.

  1973cited by this paper

• In Utero Exposure to Bisphenol a Promotes Mammary Tumor Risk in MMTV-Erbb2 Transgenic Mice Through the Induction of ER-erbB2 Crosstalk

  2020cites this paper
• Promising Immunotherapeutic Approaches in Clinical Trials

  2016cites this paper
• New insights into IL-12-mediated tumor suppression

  2014cites this paper
• The MMTV-PyVT Transgenic Mouse as a Multistage Model for Mammary Carcinoma and the Efficacy of Antineoplastic Treatment

  2013cites this paper
• HER2/neu-specific Breast Cancer Vaccine

  2013cites this paper
• Efficacy of gap junction enhancers and antineoplastic drugs in mammary carcinoma models

  2013cites this paper
• Inhibition of Neu-Induced Mammary Carcinogenesis in Transgenic Mice Expressing ERΔ3, a Dominant Negative Estrogen Receptor α Variant

  2012cites this paper
• Animal modeling of cancer pathology and studying tumor response to therapy.

  2012cites this paper
• Vaccines and other immunological approaches for cancer immunoprevention.

  2011cites this paper
• The Effects of Tamoxifen and Fish Oil on Mammary Carcinogenesis in Polyoma Middle T Transgenic Mice

  2011cites this paper
• A Short-term Rat Mammary Carcinogenesis Model for the Prevention of Hormonally Responsive and Nonresponsive In situ Carcinomas

  2009cites this paper
• An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models

  2009cites this paper
• Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.

  2009cites this paper
• Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice

  2009cites this paper
• Short-term Prophylactic Tamoxifen Reduces the Incidence of Antiestrogen-Resistant/Estrogen Receptor–Positive/Progesterone Receptor–Negative Mammary Tumors

  2009cites this paper
• Vaccination against Her2/neu - expressing cancer using chimeric virus-like particles

  2009cites this paper
• Her-2/neu Transgenic Mice for Evaluation of Immune and Antitumor Responses Against Self-Tumor Antigens in the Young and the Old

  2009cites this paper
• Antiapoptotic Small Interfering RNA as Potent Adjuvant of DNA Vaccination in a Mouse Mammary Tumor Model

  2009cites this paper
• Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model

  2008cites this paper
• S100A7 (Psoriasin), highly expressed in Ductal Carcinoma In Situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells

  2007cites this paper
• HER-2/NEU-TARGETED IMMUNOPREVENTION OF BREAST CANCER

  2007cites this paper
• Dendritic cell based cancer vaccines using adenovirally mediated expression of the HER-2/neu gene and apoptotic tumor cells expressing heat shock protein 70

  2006cites this paper
• Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv–expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion

  2006cites this paper
• Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ

  2005cites this paper
• Cancer immunoprevention.

  2005cites this paper
• The promise of genetically engineered mice for cancer prevention studies

  2005cites this paper
• Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.

  2005cites this paper
• Innovative agents in cancer prevention.

  2005cites this paper
• Sex steroid regulation of angiogenesis in breast tissue

  2005cites this paper
• New target antigens for cancer immunoprevention.

  2005cites this paper
• Sasa health exerts a protective effect on Her2/NeuN mammary tumorigenesis.

  2004cites this paper
• Characterization of the natural killer cell cytokine response to antibody-coated tumor cells.

  2004cites this paper
• Tumour-educated macrophages promote tumour progression and metastasis

  2004cites this paper